T1069

Metoclopramide hydrochloride (Metoclopramide HCl) is a selective dopamine D2 receptor antagonist, used as an antiemetic.

Numidargistat dihydrochloride (CB-1158 dihydrochloride) is an orally active and highly effective arginase (ARG1) inhibitor, an immuno-oncology agent that inhibits TGF-β2-induced subcapsular cataract by reducing the proliferation of lens epithelial cells (LEC) and decreasing the expression of fibronectin, α-SMA, collagen 1A1, and vimentin.

CB-6644 is a small molecule inhibitor of the ATPase activity of the RUVBL1/2 complex. It specifically interacts with RUVBL1/2 in cancer cells and blocks the ATPase activity of RUVBL1/2 with a half-maximal inhibitory concentration (IC50) of 15 nM[1].

CAY10595 is an antagonist of the CRTh2 (DP2) receptor with a Ki of 10 nM.

CB1 inverse agonist 1 (MRL-650) is an orally active and selective CB1 agonist. The IC50s for CB1 and CB2 are 7.5 nM and 4100 nM, respectively. CB1 inverse agonist 1 shows anorexigenic effects.

CB2 modulator 1 is a potent CB2 modulator. It can be used for the research for immune disorders, osteoporosis, inflammation, renal ischemia.

Cav 2.2 blocker 1 is an N-type calcium channel (Cav 2.2; IC50: 1 nM) blocker for the treatment of pain.

CB-1158 is a potent and orally bioavailable inhibitor of arginase (IC50s: 86 and 296 nM for recombinant human arginase 1 and 2).

CB1151, a 20-epi analogue of 1,25-dihydroxyvitamin D3, exhibits anti-tumor effects by inhibiting MCF-7 cell growth (IC50: 0.82 nM).

CB2R-IN-1 is a potent inverse agonist of the cannabinoid CB2 receptor (Ki: 0.9 nM).

CBB1003 is a new inhibitor of histone demethylase LSD1 (IC50: 10.54 μM).

CBB1007 is a potent, reversible, and substrate competitive LSD1 inhibitor (IC50: 5.27 μM for hLSD1).

CBB1007 trihydrochloride is a selective, reversible, and substrate competitive LSD1 inhibitor (IC50: 5.27 μM for hLSD1).